Oxford Global Conferences are proud to present the Inaugural Advances in Companion Diagnostics Congress, taking place on the 25-26 April 2017 in London. Over two days our event will bring together 300 senior level attendees from academia, research institutes and pharma companies to discuss the current challenges and future perspectives of companion diagnostics.
This event provides an ideal platform to participate in formal 1-1 meetings and informal networking drinks with other key industry figures, as well as providing opportunities to exchange ideas with some of the most influential professionals in the field.
Companion diagnostics are laboratory tests and test kits used to determine the suitability of patients for tailored or targeted forms of therapy, e.g., therapies that act on unique biochemical pathways or that require specific genotypes or mutations. Diagnostics are used to assist in the identification of genetic mutations with implications regarding health and treatment decisions.
Genetic testing has become an important piece of the continuously evolving health-care model. It is now possible to identify diseases before symptoms appear, predict the likelihood of disease development, and implement lifestyle or therapeutic interventions that will reduce or eliminate the effects of disease. Closer investigation into the nature of disease has sometimes revealed a more complex set of interactions than what was previously understood. While human DNA has similarities, there are also many individual differences.
On day one our esteemed speakers will discuss the progress of diagnostic development in therapeutic areas. There will be a whole stream dedicated to exploring the opportunities and challenges of diagnostic development, including the regulatory issues surround the tests, and a number of clinical case studies with a focus on biomarkers, exosome markers and glycol-biology. Day one will also focus on the current issues surrounding imaging, with a wide range of talks focussing on different imaging technologies such as digital PCR and personalised molecular imaging.
On day two the event will move more toward the advances in molecular diagnostics, with an analysis of how MDx is being applied to key areas such as auto-immune disease and oncology. We will also hear from experts discussing the use the liquid biopsy and the quest to make it more efficient. You will have the opportunity to hear from key figures as to how CDx is being used in new and exciting therapeutic areas such as primary care, rare disease and neuroscience. The conference will also focus on how CDx is being used in collaboration with NGS technologies.
This event provides an ideal platform to participate in formal 1-1 meetings and informal networking drinks with other key industry figures, as well as providing opportunities to exchange ideas with some of the most influential professionals in the field.
Companion diagnostics are laboratory tests and test kits used to determine the suitability of patients for tailored or targeted forms of therapy, e.g., therapies that act on unique biochemical pathways or that require specific genotypes or mutations. Diagnostics are used to assist in the identification of genetic mutations with implications regarding health and treatment decisions.
Genetic testing has become an important piece of the continuously evolving health-care model. It is now possible to identify diseases before symptoms appear, predict the likelihood of disease development, and implement lifestyle or therapeutic interventions that will reduce or eliminate the effects of disease. Closer investigation into the nature of disease has sometimes revealed a more complex set of interactions than what was previously understood. While human DNA has similarities, there are also many individual differences.
On day one our esteemed speakers will discuss the progress of diagnostic development in therapeutic areas. There will be a whole stream dedicated to exploring the opportunities and challenges of diagnostic development, including the regulatory issues surround the tests, and a number of clinical case studies with a focus on biomarkers, exosome markers and glycol-biology. Day one will also focus on the current issues surrounding imaging, with a wide range of talks focussing on different imaging technologies such as digital PCR and personalised molecular imaging.
On day two the event will move more toward the advances in molecular diagnostics, with an analysis of how MDx is being applied to key areas such as auto-immune disease and oncology. We will also hear from experts discussing the use the liquid biopsy and the quest to make it more efficient. You will have the opportunity to hear from key figures as to how CDx is being used in new and exciting therapeutic areas such as primary care, rare disease and neuroscience. The conference will also focus on how CDx is being used in collaboration with NGS technologies.
